On July 9, 2019 Be The Match BioTherapies, an organization offering solutions for companies developing and commercializing cell and gene therapies, and Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company, reported a partnership to accelerate patient access to life-saving cell therapies (Press release, Be The Match BioTherapies, JUL 9, 2019, View Source [SID1234537442]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The collaboration leverages Be The Match BioTherapies’ industry-leading cell therapy supply chain and collection network management expertise to support clinical development of Tmunity’s diversified portfolio of novel treatments that exhibit best-in-class control over T cell activation and direction in the body. These personalized next-generation immunotherapies for cancer are advancing through preclinical and clinical testing.

"It’s an exciting moment for Tmunity as we widen our clinical pipeline of investigational immunotherapies to address a broad range of solid tumor and hematological cancers—and Be The Match BioTherapies is the ideal partner to help advance that work," said Usman "Oz" Azam, MD, president and chief executive officer of Tmunity. "We look forward to working together to deliver powerful new options for patients and to bring about the future of cell therapy."

Be The Match BioTherapies will support Tmunity’s ongoing work to advance T cell immunotherapies. These efforts will include the management of cell therapy supply chain and logistics, supported by the company’s MatchSource Supply Chain Software. In addition, Be The Match BioTherapies will qualify, develop and train a network of collection centers to help ensure the collection of consistent, compliant and high-quality cell starting material. To gain efficiencies in site qualification, Tmunity will receive licensed access to quality system audit results through the Quality System Audit Program (QSAP).

"Be The Match BioTherapies was built to empower the development and delivery of next-generation cell and gene therapies like those being developed by Tmunity," said Chris McClain, MBA, vice president, Sales and New Business Development, Be The Match BioTherapies. "We are eager to help speed access to Tmunity’s innovative therapies for patients in need."